Local recurrence of sinonasal renal cell-like adenocarcinoma
A CARE compliant case report

Jian Wu, MDa, Qin Fang, MDb, Yu-Jie He, MDb∗, Wei-Xiang Chen, PhDb, Yu-Kai Qi, MDb, Jun Ding, MDa

Abstract
Rationale: Sinonasal renal cell-like adenocarcinoma (SNRCLA) is a very rare sino-nasal carcinoma. Because SNRCLA has the same morphological features as other clear cell carcinomas, and some of them also occurred in sinonasal part, it is necessary to differentiate SNRCLA from these tumors.

Patient concerns: A 42-year-old man presented with complaints of epistaxis for 1 day. The patient had undergone endoscopic resection of a neoplasm in the right nasal passage at another hospital 35 months before and was diagnosed with SNRCLA at that time, and did not receive any other adjuvant therapy.

Diagnoses: The postoperative histopathological examination revealed a diagnosis of recurrent SNRCLA.

Interventions: The tumor was removed under nasal endoscopy.

Outcomes: The patient was followed up for 2 months and recovered well without any complications.

Lessons: NSRCLA is a very rare tumor, and should be differentiated from other clear cell tumors including some salivary tumors and metastatic tumors of renal and thyroid.

Abbreviations: ACC = acinic cell carcinoma, CCFTC = clear cell variant follicular thyroid carcinoma, CCPRCC = clear cell papillary variant renal cell carcinoma, CCRCC = clear cell variant renal cell carcinoma, EMC = epithelial–myoepithelial carcinoma, RCC = renal cell carcinoma marker, SCCC = salivary clear cell carcinoma, SNRCLA = sinonasal renal cell-like adenocarcinoma.

Keywords: differentiation, metastatic CCRCC, recurrent, SCCC, SNRCLA

1. Introduction

Sinonasal renal cell-like adenocarcinoma (SNRCLA) is a very rare tumor that occurs in the sinonasal part because that there are only about 20 reported cases in English literature since the first 2 SNRCLA cases were reported in 2002.[1,2] SNRCLA has the microscopic features similar to some metastatic sinonasal carcinomas including clear cell renal cell carcinoma (CCRCC) and follicular thyroid carcinoma.[3–5]

The morphology of SNRCLA was so mild that people once questioned whether it was suitable to name it adenocarcinoma instead of benign adenoma.[6] However, in spite of most patients with SNRCLA received adjuvant radiotherapy after surgery, accumulating data revealed that about 20% patients with SNRCLA still had tumor recurrence.[6–7] Here, we reported a case of recurrent SNRCLA in the right ethmoid sinus 35 months after tumor removal. This study was approved by the Ethical Committee of Second Military Medical University Gongli Hospital (No. 2018-75). Informed written consent was obtained from the patient for publication of this case report and accompanying images.

2. Case presentation

A 42-year-old man presented with complaints of epistaxis for 1 day, and computed tomography scan showed a soft tissue mass with increased density in the right ethmoid sinus (Fig. 1). In the past, the patient had undergone endoscopic resection of a neoplasm in the right nasal at another hospital 35 months ago. The patient was diagnosed with SNRCLA at that time and did not receive any other treatments such as chemoradiotherapy after surgery. According to the patient’s history, we considered the patient as the recurrence of SNRCLA. Under general anesthesia, the nasal mucosa surface was conversed with 0.11% adrenalin, and the neoplasm in the right ethmoid sinus was removed.

Macroscopically, the tumor was composed of a pile of gray-white, broken tissue measuring 1.5 cm in diameter. The tumor was mainly composed of clear cells, which might be mildly acidophilic, and had small blood vessels in the tumor stroma (Fig. 2A). The clear cells were arranged with solid, tubular and follicular structure, and eosinophilic secretions were visible in the lumen, similar to that of thyroid tissue (Fig. 2B). The heterogeneity of clear cells was very small due to mild nucleus and rare mitosis (Fig. 2C). Hemorrhage of tumor stromal tissue

Editor: N/A.

The authors have no conflicts of interest to disclose.

* Department of Pathology, ‡ Department of Otolaryngology, Gongli Hospital, Second Military Medical University, Shanghai, China.

Correspondence: Yu-Jie He, Gongli Hospital Second Military Medical University, Pudong New Area, Shanghai 200135, China (e-mail: Drlipei@126.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2019) 98(7):e14533
Received: 5 October 2018 / Received in final form: 10 January 2019 / Accepted: 23 January 2019
http://dx.doi.org/10.1097/MD.0000000000014533
was obvious in focal areas, like that of CCRCC (Fig. 2D). The tumor cells were positive for CAX9 (Fig. 3A), CK7 (Fig. 3B), S100 (Fig. 3C), SOX10 (Fig. 3D), Vimentin (Fig. 3E), and EMA, whereas negative for CD10, P63, TTF-1, and Pax-8. The index of Ki67 was about 2% (Fig. 3F). According to both morphological and immunohistochemical features, the diagnosis of SNRCLA recurrence was made. The patient recovered well and was discharged on the fourth postoperative day without any complications. The patient was followed up for 2 months and recovered well without any complications.

3. Discussion

SNRCLA is a rare, low-grade neoplasm that bears no resemblance to any other sinonasal primary tumor.[8] The tumor has a female predominance of 2:1. The clinical manifestations are relatively nonspecific including epistaxis, nasal obstruction, headache, and olfactory impairment. The nasal cavity is the most common site of involvement, followed by paranasal sinuses and nasopharynx.

As showed in Table 1, SNRCLA should be differentiated from other clear cell tumors due to the similar morphological features, including salivary tumors and metastatic clear cell carcinomas or clear cell variant thyroid follicular carcinoma. Salivary clear cell carcinomas (SCCCs) mostly occurred in the oral cavity with the clinical presentation of swelling and mucous ulcer. SCCC were usually smaller than 3 cm in size with an infiltrative growth pattern.[9] Monomorphous polygonal clear cells and stromal

Figure 1. CT scan revealed a soft tissue mass with increased density in the right ethmoid sinus (A, as showed by the asterisk). CT = computed tomography.

Figure 2. Histopathological features of SNRCLA. The tumor was mainly composed of clear cells, which might be mildly acidophilic, and had small blood vessels in the tumor stroma (A). The clear cells were arranged with solid, tubular and follicular structure, and eosinophilic secretions were visible in the lumen, similar to that of thyroid tissue (B). The heterogeneity of clear cells was very small due to mild nucleus and rare mitosis (C). Hemorrhage of tumor stromal tissue was obvious in focal areas, like that of CCRCC (D). CCRCC = clear cell variant renal cell carcinoma, SNRCLA = sinonasal renal cell-like adenocarcinoma.
Table 1
Recurrent cases of SNRCLA.

| Author   | Age, Sex | Tumor site         | Treatment                              | Follow up          |
|----------|----------|--------------------|----------------------------------------|--------------------|
| Heffner[7] | 62, F    | Nasal              | Surgery, adjuvant radiotherapy          | Recurrence at 3 and 5 yr |
| Shen[6]   | 56, F    | Nasal, skull base  | Surgery, adjuvant radiotherapy          | Recurrence at 22 mo  |
| Shen[6]   | 89, F    | Sinonasal          | Surgery                                | Recurrence at 4 mo  |
| Shen[6]   | 73, M    | Nasal              | Surgery, adjuvant radiotherapy          | Recurrence at 20 mo  |
| Present case | 42, M   | Sinonasal          | Surgery                                | Recurrence at 35 mo  |

SNRCLA = sinonasal renal cell-like adenocarcinoma.

Figure 3. Immunohistochemical features of SNRCLA. Tumor cells were positive for CAX9 (A), CK7 (B), S100 (C), SOX10 (D), and Vimentin (E), and the index of Ki67 was about 2% (F). SNRCLA = sinonasal renal cell-like adenocarcinoma.
hyalinization were the main morphological characteristics of SCCC. The tumor cells were positive for CK, but negative for S100 and CEA. Therefore, the sites of sinus and nasal cavity, no stromal hyaline degeneration and positive expression of S100 could help to diagnosis of EMC.10 Acinic cell carcinomas (ACCs) also occurred in parotid with the microscopic features of spindled cells and basement membrane deposition. The expression of myoepithelial marker P63/SMA could help the diagnosis of EMC.10 Acinic cell carcinomas (ACCs) also occurred in parotid with slow-growing mass. The large, polygonal tumor cells and the stromal infiltration of lymphoid were morphological characteristics of ACC. Tumor cells had the positive expression of PSA and α1-antitrypsin, which were negative for the tumor cells of SNRCLA.11

The most important mimic of SNRCLA was metastatic CCRCC because both tumors had similar clear cells and a common background of hemorrhage. However, the nuclei heterogeneity and tumor necrosis of CCRCC were obvious. Tumor cells of CCRCC expressed positively CD10 and renal cell carcinoma marker (RCC), whereas SNRCLAs did not express these markers. In addition, clear cell papillary renal cell carcinoma (CCPRCC) also diffusely expressed CK7 and CA19 like that of SNRCLAs, but CCPRCC is a low-grade, indolent neoplasm with not any report of the distant metastasis. CCPRCC expressed GATA3, which was negative for SNRCLA cells.12

SNRCLA also should be differentiated from clear cell variant thyroid follicular carcinomas (CCTFC) because that both tumors had similar follicular structures composed of clear cells and eosinophilic secretions in the lumens. The tumor cells of CCTFC were positive for CK19 and TTF-1, which were negative for SNRCLA cells.13

SNRCLA was considered as a low-grade malignancy due to mild morphological features. Although no metastatic case of SNRCLA has been reported, there were approximately 20% patients, who had a local recurrence. We summarized all the recurrent SNRCLA cases in English literature at Table 2. Recurrent patients included 3 female and 2 male patients. For the 17 patients with follow-up data, 33% (3/9) patients with postoperative radiotherapy relapsed whereas only 25% (2/8) patients without postoperative radiotherapy relapsed.6,7 Therefore, we could infer that radiotherapy seemed not to work on the treatment of SNRCLAs.

4. Conclusions

SNRCLA is a very rare tumor, and we should differentiate it from other clear cell tumors including some salivary tumors, metastatic CCRCC/CCPRCC, and metastatic CCTFC.

Acknowledgments

The authors thank the Weak Structure Construction Foundation of Pudong New Area Health Planning Commission, Shanghai, China (No. PWZbr2017-21) for the support.

Author contributions

Conceptualization: Yu-Jie He.
Investigation: Qin Fang.
Methodology: Jun Ding.
Project administration: Yu-Jie He.
Resources: Wei-Xiang Chen, Qin Fang.
Supervision: Jun Ding.
Validation: Yu-Kai Qi.
Visualization: Yu-Kai Qi.
Writing – original draft: Jian Wu.
Writing – review and editing: .
Writing – review and editing: Wei-Xiang Chen, Jian Wu.

References

[1] Zur KB, Brandwein M, Wang B, et al. Primary description of a new entity, renal cell-like carcinoma of the nasal cavity: van Meegeren in the house of Vermeer. Arch Otolaryngol Head Neck Surg 2002; 128:441–7.
[2] Moh’d HU, Kahrwaij GJ, Muffarrij AA, et al. Low grade primary clear cell carcinoma of the sinonasal tract. Rhinology 2002;40:44–7.
[3] Dinçhas FO, Atalar B, Oksuz DC, et al. Unusual metastasis of renal cell carcinoma to the nasal cavity. J BUON 2004;9:201–4.
[4] Jean T, Pourang D, Gabikian P, et al. Unilateral nasal congestion and headache: renal cell carcinoma metastasis to the sinuses. J Allergy Clin Immunol Pract 2017;5:1122–4.
[5] Cumberworth VL, Obiri A, Morrissey G, et al. Late sino-nasal metastasis from follicular thyroid carcinoma. J Laryngol Otol 1994;108:1010–1.
[6] Shen T, Shi Q, Velosa C, et al. Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression. Hum Pathol 2015;46:1598–606.
[7] Brandwein-Gensler M, Wei S. Envisioning the next WHO head and neck classification. Head Neck Pathol 2014;8:1–5.
[8] Zhao W, Yang L, Wang L, et al. Primary clear cell carcinoma of nasal cavity: report of six cases and review of literature. Int J Clin Exp Med 2014;7:5469–76.

Table 2

| Tumors’ name | SCCC | Salivary tumors | ACC | Metastatic CCRCC | CCPRCC | CCTFC | SNRCLA |
|--------------|------|----------------|-----|-----------------|--------|--------|--------|
| Localization | Oral cavity | Parotid, minor gland | Parotid | Head and neck metastases, not nasal metastases | No lymph node or other metastases | Metastases of head and neck, not sinus | Sinus, nasal cavity |
| Presentation | Swelling, ulcer | Painless, slow-growing mass | Slow-growing mass | Hematouria, renal pain | Non-specific, good prognosis | Thyroid mass | Hematouria, nasal obstruction |
| Gross features | <3 cm, Infiltrating growth | Multinodular mass, expansive nodules | 1–3 cm, Circumscribed nodules | Bleeding, necrosis, clear border | Solid arrangement, nuclear heterogeneity | Papilla arrangement of eosinophilic cells | Polypoid or submucosal mass |
| Microscopic features | Monomorphous polygonal clear cell, stromal hyalinization | Spindled cells, basement membrane deposition | Large, polygonal cells, lymphoid infiltration | VINI+, CK7+, RCC+ | VINI+, CK7+, RCC+ | VINI+, CK7+, RCC+ | VINI+, CK7+, S100+ |
| Immunohistochemical features | α1-antitrypsin+ | α1-antitrypsin+ | α1-antitrypsin+ | VINI+, CK7+, RCC+ | VINI+, CK7+, RCC+ | VINI+, CK7+, RCC+ | VINI+, CK7+, S100+ |

ACC = acinic cell carcinoma, CTCFF = clear cell variant follicular thyroid carcinoma, CCPRCC = clear cell papillary renal cell carcinoma, CCRCC = clear cell variant renal cell carcinoma, EMC = epithelial-myepithelial carcinoma, RCC = renal cell carcinoma marker, SCCC = salivary clear cell carcinoma, SNRCLA = sinonasal renal cell-like adenocarcinoma.
[9] Wang B, Brandwein M, Gordon R, et al. Primary salivary clear cell tumors – a diagnostic approach: a clinicopathologic and immunohistochymical study of 20 patients with clear cell carcinoma, clear cell myoepithelial carcinoma, and epithelial-myoepithelial carcinoma. Arch Pathol Lab Med 2002;126:676–85.

[10] Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol 2007;31:44–57.

[11] Federspil PA, Constantinidis J, Karapantzos I, et al. Acinic cell carcinomas of the parotid gland. A retrospective analysis. HNO 2001;49:825–30.

[12] Mantilla JG, Antic T, Tretiakova M. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics. Hum Pathol 2017;66:152–8.